Corona Remedies IPO: Initial Trading Performance Analyzed

Corona Remedies, a pharmaceutical company focused on women’s health and related areas, started trading strongly on the BSE. Shares were priced at Rs 1,465.55 at 10:20 IST on December 5, 2025, a significant premium to the initial offering price of Rs 1,062. This indicates high investor confidence in the company’s potential. The stock debuted at Rs 1,452, reflecting a 36.72% premium at the time.

Key Points

• Shares traded at Rs 1,465.55, a 38% premium over IPO price.
• Initial listing price was Rs 1,452, a 36.72% premium.
• High trading volume: 6.64 lakh shares traded so far.
• IPO was fully subscribed 137.04 times, demonstrating strong demand.
• Major investors contributed Rs 194.85 crore through anchor investors.
• Company’s revenue primarily from women’s health and cardio-diabeto.

The IPO itself was a significant event, raising Rs 655.37 crore through a sale of shares by existing shareholders. These shareholders included Dr. Kirtikumar Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, Brinda Ankur Mehta, Sepia Investments, Anchor Partners, and Sage Investment Trust. A key detail is that the promoters held 72.5% of the company before the IPO, which is expected to drop to around 69% after the offering.

Corona Remedies develops and sells medicines in areas like women’s health, managing diabetes and heart conditions, dealing with pain, and treating urinary problems. The company’s sales are mostly driven by its women’s health and cardio-diabeto products, accounting for about 53.19% of its revenue in the first quarter of fiscal year 2026.

As of June 30, 2025, Corona Remedies had 71 different medicine brands across these therapeutic areas, alongside other products like vitamins, minerals, and nutrition (VMN). The vast majority – 96.34% – of the company’s sales came from India, with just a small portion, 3.66%, exported.

Leading sales are concentrated in the western part of India – states like Gujarat, Maharashtra, Goa, Madhya Pradesh, and Chhattisgarh. Before the IPO, Corona Remedies secured funding from 17 anchor investors, raising Rs 194.85 crore by selling 18.34 million shares at a price of Rs 1,062 each. Recent financial results show a strong performance, with the company reporting a consolidated net profit of Rs 46.20 crore and sales of Rs 346.54 crore for the three months ending September 30, 2025.

Strong initial trading suggests investor confidence in Corona Remedies’ growth potential.